Endometriosis is a common gynecological disease. It is a gynecological disease caused by the
growth and reproduction of the endometrium beyond the surface of the uterine tissue and
organs, which causes recurrent abdominal pain, infertility and other main symptoms.
The recurrence of endometriosis and the side effects of medication have troubled clinicians
and patients for a long time and the search for new drugs is going on all the time.
Honghuaruyi Wan is the traditional Tibetan prescription, clinical research has proved that
Honghuaruyi Wan can significantly reduce risk mouse dysmenorrhea caused by oxytocin, improve
dysmenorrhea model of mice body torsion times and improve the estrogen and progestogen
operator Netherlands rat pituitary estradiol and prolactin level, at the same time also can
reduce the amount of TNF alpha, thus improving endometriosis dysmenorrhea.
In this study, the therapeutic effects of Honghuaruyi Wan provided by Tibet Qizheng Tibetan
Medicine Co.,Ltd on secondary dysmenorrhea in patients with endometriosis was evaluated
clinically. A multi-center, randomized, double-blind, placebo-controlled clinical trial was
designed to provide evidence-based medical evidence for Honghuaruyi Wan in the treatment of
endometriosis dysmenorrhea. In the design of this trial, the therapeutic effects and safety
of Honghuaruyi Wan in the treatment of dysmenorrhea secondary to endometriosis were evaluated
with Honghuaruyi Wan in the treatment group and placebo in the control group.